ACRS vs. PRTA, BCAX, CRMD, QURE, ETNB, DNTH, CGEM, PHAR, ABUS, and LENZ
Should you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Prothena (PRTA), Bicara Therapeutics (BCAX), CorMedix (CRMD), uniQure (QURE), 89bio (ETNB), Dianthus Therapeutics (DNTH), Cullinan Therapeutics (CGEM), Pharming Group (PHAR), Arbutus Biopharma (ABUS), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry.
Aclaris Therapeutics vs.
Aclaris Therapeutics (NASDAQ:ACRS) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.
98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 6.4% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 28.1% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Aclaris Therapeutics has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Prothena had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 3 mentions for Prothena and 2 mentions for Aclaris Therapeutics. Prothena's average media sentiment score of 1.39 beat Aclaris Therapeutics' score of 1.14 indicating that Prothena is being referred to more favorably in the news media.
Prothena received 223 more outperform votes than Aclaris Therapeutics when rated by MarketBeat users. Likewise, 70.42% of users gave Prothena an outperform vote while only 66.67% of users gave Aclaris Therapeutics an outperform vote.
Aclaris Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500.
Aclaris Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 328.02%. Prothena has a consensus price target of $46.50, suggesting a potential upside of 237.69%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aclaris Therapeutics is more favorable than Prothena.
Prothena has a net margin of -98.86% compared to Aclaris Therapeutics' net margin of -136.65%. Prothena's return on equity of -24.19% beat Aclaris Therapeutics' return on equity.
Summary
Prothena beats Aclaris Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Aclaris Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclaris Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ACRS) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ACRS Stock Alerts